Kimia Farma (KAEF) Records Performance Recovery Following 2025 Restructuring

JAKARTA, KOMPAS.com – PT Kimia Farma (Persero) Tbk (KAEF) has reported a trend of improvement in its fundamental financial performance throughout the 2025 fiscal year. This aligns with the implementation of strategic steps in business restructuring and transformation. The company announced its audited consolidated financial statements for the period ending 31 December 2025. Throughout 2025, KAEF recorded a significant decline in the cost of goods sold to Rp 6.16 trillion, compared to Rp 6.99 trillion in 2024. This reduction was followed by a 12.65% depreciation in operating expenses, from Rp 3.79 trillion to Rp 3.31 trillion. The company stated that cost efficiency was one of the main factors driving the performance recovery. “The cost of goods sold was successfully reduced to Rp 6.16 trillion from Rp 6.99 trillion in 2024,” Kimia Farma wrote in an official statement on Monday (6/4/2026). This increase was driven by a focus on products with higher margins as well as optimisation of the product portfolio. On the other hand, the company significantly reduced its net loss. The loss for the current year fell by 63.3%, from Rp 1.21 trillion in 2024 to Rp 443.36 billion in 2025. The reduction is also reflected in the basic loss per share, which shrank from Rp 151.31 to Rp 60.17. In addition, KAEF’s liability structure also showed improvement. Short-term liabilities decreased from Rp 7.91 trillion to Rp 7.06 trillion. The most significant reduction occurred in short-term bank debt, which fell from Rp 3.06 trillion to Rp 1.09 trillion. To maintain business sustainability, KAEF is carrying out a comprehensive business transformation across all business lines. This transformation is focused on strengthening business fundamentals through six strategic pillars, namely working capital resilience, strengthening human resource competencies, business process digitalisation, operational efficiency, strengthening corporate governance, and synergy among group entities. The company is also sharpening its business focus by prioritising the development and marketing of products with higher margins.